clinical trial · NCT06581406
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.·phase3·recruiting·n = 280
Metastatic Uveal MelanomaRP2IpilimumabNivolumab
brief summary
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
started
Dec 17, 2024
primary completion
Jan 1, 2030
completion
Oct 1, 2031
last updated
Apr 2, 2026
official title
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol